" /> 【特別寄稿】肺癌薬物療法50年の歩み■福岡正博 |
呼吸臨床

【特別寄稿】肺癌薬物療法50年の歩み

福岡正博*

*和泉市立総合医療センター腫瘍内科（〒594-0073　大阪府和泉市和気町4-5-1）


Progress of chemotherapy in lung cancer

Masahiro Fukuoka*

*Department of Medical Oncology, Izumi City General Hospital, Izumi


Keywords：肺癌，化学療法，殺細胞性抗癌薬，分子標的薬，免疫チェックポイント阻害薬／lung cancer，chemotherapy，cytotoxic drug，molecular targeted drug，immune checkpoint inhibitor


呼吸臨床 2018年2巻12号　論文No.e00064
Jpn Open J Respir Med 2018 Vol. 2 No. 12 Article No.e00064

DOI: 10.24557/kokyurinsho.2.e00064


掲載日：2018年12月21日


©️Masahiro Fukuoka. 本論文の複製権，翻訳権，上映権，譲渡権，貸与権，公衆送信権（送信可能化権を含む）は弊社に帰属し，それらの利用ならびに許諾等の管理は弊社が行います。


要旨

　肺癌の薬物療法について50年の歩みを振り返った。小細胞肺癌は，1970〜1990年にさまざまな戦略が検討されたが，この20年はほとんど進歩していない。非小細胞肺癌では，cisplatinの登場以来，明らかな延命が認められたがその効果は限定的であった。21世紀になって，gefitinibをはじめ多くのドライバー遺伝子変異を標的とした分子標的薬が開発されパラダイムシフトが起こった。そして，免疫チェックポイント阻害薬の登場でさらなる進歩がもたらされている。

文献

  1. Fukuoka M, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst. 1991; 83: 855-61.
  2. Roth BJ, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992; 10: 282-91.
  3. Furuse K, et al. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. J Clin Oncol. 1998; 16:2126-32.
  4. Murray N, et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol. 1999; 17: 2300-8.
  5. Noda K, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002; 346:85-91.　
  6. Lara PN Jr, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol.2009; 27: 2530-5.
  7. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995; 311: 899-909.
  8. Kawahara M, et al. A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma. Cancer.  1991; 68: 714-9.
  9. Fukuoka M, et al. A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. J Clin Oncol. 1991; 9: 606-513.
  10. Schiller JH, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 92-8.
  11. Ohe Y, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2007; 18: 317-23.
  12. Kubota K, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol. 2004; 22: 254-61.
  13. Scagliotti G, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26: 3543-51.
  14. Negoro S, et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst. 1991; 83: 1164-8.
  15. Negoro S, et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer.Br J Cancer. 2003; 88: 335-41.
  16. Nakagawa K,　et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol. 2003 ; 14: 922-30.
  17. Fukuoka M, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) J Clin Oncol. 2003; 21: 2237-46.
  18. Paez JG, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-500.
  19. Lynch T, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-39.
  20. Mok TS, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-57.
  21. Mitsudomi T, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405). an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11: 121-8.
  22. Maemondo M, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362: 2380-8.
  23. Park K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016; 17: 577-89.
  24. Soria JC, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018; 378: 113-25.
  25. Soda M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448: 561-6.
  26. Hida T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017; 390: 29-39.
  27. Brahmer, J et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015; 373: 123-35.
  28. Borghaei H, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015; 373: 1627-39.
  29. Herbst RS, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016; 387: 1540-50.
  30. Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016; 375: 1823-33.

続きを見る

ログイン

新規登録

会員登録





※ご登録の前に個人情報保護方針をご一読ください。

登録

パスワードを忘れた方


送信